Moher David
BMC Med. 2014 Oct 24;12:214. doi: 10.1186/s12916-014-0214-2.
Transparently documenting who and why a person is an author of a clinical trial report, as with any other article, is important since it allows research team members appropriate recognition and also likely helps reduce or avoid problems such as ghost authorship. Marušić and colleagues have previously proposed a five-step framework for attributing authorship of pharmaceutical company-sponsored clinical trials. The process is short, easily implemented, and can be used in addition to the authorship guidance provided by the International Committee of Medical Journal Editors. For the framework to gain optimal traction it is important that a strong implementation plan is developed and carried out across a broad spectrum of stakeholders. Authorship brings with it important responsibilities; authors must ensure that articles baring their names must be fit for purpose. This will help guarantee an increased value for published reports of clinical trials.
与其他任何文章一样,透明地记录一个人成为临床试验报告作者的人员身份及原因很重要,因为这能让研究团队成员得到恰当认可,也可能有助于减少或避免诸如“幽灵作者”等问题。马鲁希奇及其同事此前提出了一个用于确定制药公司赞助的临床试验作者身份的五步框架。该流程简短、易于实施,并且可以在医学期刊编辑国际委员会提供的作者身份指南之外使用。为使该框架获得最佳影响力,制定并在广泛的利益相关者中执行强有力的实施计划很重要。作者身份伴随着重要责任;作者必须确保署有他们名字的文章要符合目的。这将有助于保证临床试验发表报告的价值得到提升。